Associate Professor, Pediatric Endocrinologist, Pediatrics Department, School of Medicine, Hamedan University of Medical Sciences, Hamedan, Iran.
Pediatric Senior Resident, Department of Pediatrics, School of Medicine, Hamedan University of Medical Sciences, Hamedan, Iran.
Endocrine. 2018 Aug;61(2):267-274. doi: 10.1007/s12020-018-1635-z. Epub 2018 May 24.
To compare the safety/efficacy of intermittent subcutaneous rapid-acting insulin aspart with the standard low-dose intravenous infusion protocol of regular insulin for treatment of pediatric diabetic-ketoacidosis.
For a prospective randomized-controlled clinical trial on 50 children/adolescents with mild/moderate diabetic-ketoacidosis, the diagnostic criteria for ketoacidosis included: blood glucose level >250 mg/dl, ketonuria>++, venous pH <7.3 and/or bicarbonate <15 mEq/l.
age, sex, clinical/laboratory parameters including blood sugar, arterial blood gases, urine ketones, severity of diabetic-ketoacidosis, amount of insulin administered to correct acidosis, time to recover from diabetic-ketoacidosis, number of days of hospitalization, and complications. Patients were randomly assigned to intervention (subcutaneous) and control (intravenous) groups. Controls received 0.05-0.1 unit/kg/hour intravenous regular insulin infusion until resolution of diabetic-ketoacidosis and stayed in the intensive care unit. Interventions received 0.15 unit/kg subcutaneous insulin aspart every two hours and stayed in regular medical ward.
From 50 children (age 2-17 years), 56% (28) were females, and 48% (24) had established-type I diabetes. Intervention and control groups had similar baseline clinical/laboratory findings. Average age (years) was 8.6 ± 0.8 for intervention and 8.86 ± 0.7 for control group (p = 0.4) with 64% having moderate diabetic-ketoacidosis. The mean total-dose of insulin units needed for treatment of diabetic-ketoacidosis in intervention (subcutaneous insulin aspart) was lower than controls (intravenous regular insulin) (p < 0.001). No mortality/serious events happened. Three diabetic-ketoacidosis recurrences among interventions and one among controls occurred.
To manage mild/moderate diabetic-ketoacidosis in children/adolescents, subcutaneous rapid-acting insulin aspart is an alternative to intravenous infusion of regular insulin. Subcutaneous insulin treated moderate DKA with faster recovery/shorter hospital stay.
比较间歇性皮下速效胰岛素与常规胰岛素标准小剂量静脉输注方案治疗儿科糖尿病酮症酸中毒的安全性/疗效。
对 50 例轻/中度糖尿病酮症酸中毒患儿/青少年进行前瞻性随机对照临床试验,酮症酸中毒的诊断标准包括:血糖水平>250mg/dl、尿酮体+++、静脉 pH 值<7.3 和/或碳酸氢盐<15mEq/l。
年龄、性别、临床/实验室参数,包括血糖、动脉血气、尿酮体、糖尿病酮症酸中毒严重程度、纠正酸中毒所需胰岛素用量、恢复时间、住院天数及并发症。患者随机分为干预(皮下)组和对照组(静脉)组。对照组给予 0.05-0.1 单位/kg/h 静脉常规胰岛素输注,直至糖尿病酮症酸中毒缓解,并入住重症监护病房。干预组给予 0.15 单位/kg 皮下胰岛素类似物每 2 小时一次,并入住普通病房。
50 例患儿(年龄 2-17 岁)中,56%(28 例)为女性,48%(24 例)为 1 型糖尿病。干预组和对照组的基线临床/实验室检查结果相似。干预组平均年龄(岁)为 8.6±0.8,对照组为 8.86±0.7(p=0.4),64%为中度糖尿病酮症酸中毒。干预组(皮下胰岛素类似物)治疗糖尿病酮症酸中毒所需的胰岛素总剂量低于对照组(静脉常规胰岛素)(p<0.001)。无死亡/严重不良事件发生。干预组有 3 例糖尿病酮症酸中毒复发,对照组有 1 例复发。
在儿童/青少年中,管理轻/中度糖尿病酮症酸中毒时,皮下速效胰岛素类似物是静脉输注常规胰岛素的替代方案。皮下胰岛素治疗中度 DKA 可更快恢复/缩短住院时间。